Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
PE-22-28: Evidence Summary
Evidence summary for PE-22-28 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to PE-22-28 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Depression | Tier D | 0 | Mouse behavioral models only; zero human studies |
| Neurogenesis | Tier D | 0 | Rodent hippocampal data only; no human confirmation |
References (2)
- Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design — Mazella J, Petrault O, Lucas G, et al. . PLoS Biology (2010) PMID: 20405001
- PE 22-28, a novel spadin analog, shows antidepressant-like activity and modulates hippocampal neurogenesis — Djelloul M, Bhatt S, Bhatt R, et al. . Neuropharmacology (2015) PMID: 28955242